Joint Presentation from Boehringer Ingelheim and Biota at GTCbio’s 5th Anti-Infectives Partnering & Deal-Making Summit (March 5-7, 2008, Philadelphia, PA)
Monrovia, CA, January 09, 2008 --(PR.com)-- James Chafouleas, Director of Global Licensing – Virology at Boehringer Ingelheim and Leigh Farrell, Vice President of Business Development at Biota will give a joint presentation entitled “Making the Right Deal: It’s Not Just About the Money” at GTCbio’s 5th Anti-Infectives Partnering & Deal-Making Summit taking place on March 5-7 2008 in Philadelphia, PA.
In November 2006, Biota Holdings Limited (Biota), an Australian biotechnology company signed a $102m collaboration and license agreement with Boehringer Ingelheim for its discovery-stage HCV nucleoside analogue program. Biota’s licensing strategy for its HCV nucleoside program involved pursuing full contract negotiations with multiple parties. Key drivers for Biota’s selection of Boehringer Ingelheim were Boehringer Ingelheim’s expertise in the field of HCV, the cultural fit between the scientists and management of both companies, and Boehringer Ingelheim’s high-level buy-in and strong record of good alliance management. The collaboration has been operating productively for over twelve months. Dr. James Chafouleas, Director of Global Licensing - Virology at Boehringer Ingelheim and Dr. Leigh Farrell, Vice President of Business Development at Biota will present their respective strategies for pursuing the deal and report on the alliance management process that has been adopted to manage this long distance relationship.
The conference also features presentations from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Human Genome Sciences, Merck, Novartis, Wyeth and many more. The full agenda is available online at www.gtcbio.com.
The 5th Anti-Infectives Partnering & Deal Making Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant anti-infective issues and deals that will affect the industry.
This event also provides a unique venue for attendees to learn about the anti-infective business development trends, the infectious disease markets, and novel technologies that shape up the industry. For more information, please visit www.gtcbio.com.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
###
In November 2006, Biota Holdings Limited (Biota), an Australian biotechnology company signed a $102m collaboration and license agreement with Boehringer Ingelheim for its discovery-stage HCV nucleoside analogue program. Biota’s licensing strategy for its HCV nucleoside program involved pursuing full contract negotiations with multiple parties. Key drivers for Biota’s selection of Boehringer Ingelheim were Boehringer Ingelheim’s expertise in the field of HCV, the cultural fit between the scientists and management of both companies, and Boehringer Ingelheim’s high-level buy-in and strong record of good alliance management. The collaboration has been operating productively for over twelve months. Dr. James Chafouleas, Director of Global Licensing - Virology at Boehringer Ingelheim and Dr. Leigh Farrell, Vice President of Business Development at Biota will present their respective strategies for pursuing the deal and report on the alliance management process that has been adopted to manage this long distance relationship.
The conference also features presentations from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Human Genome Sciences, Merck, Novartis, Wyeth and many more. The full agenda is available online at www.gtcbio.com.
The 5th Anti-Infectives Partnering & Deal Making Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant anti-infective issues and deals that will affect the industry.
This event also provides a unique venue for attendees to learn about the anti-infective business development trends, the infectious disease markets, and novel technologies that shape up the industry. For more information, please visit www.gtcbio.com.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
###
Contact
GTCbio
Tiffany Chin
626-256-6405
www.gtcbio.com
Tiffany Chin
626-256-6405
www.gtcbio.com
Contact
Categories